Peer-reviewed veterinary case report
Treating sarcoptic mange in dogs with NexGard and NexGard Spectra
By Hampel, Verena et al.·Published in Parasite (Paris, France)·2018·Conreso GmbH, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of canine sarcoptic mange with afoxolaner (NexGard) and afoxolaner plus milbemycin oxime (NexGard Spectra) chewable tablets: efficacy under field conditions in Portugal and Germany.
- Species:
- dog
Plain-English summary
A group of dogs with sarcoptic mange, which causes severe itching, skin lesions, and hair loss, were treated with either NexGard or NexGard Spectra, both given twice a month apart. After treatment, the dogs showed a remarkable reduction in the number of live mites and significant improvement in their skin symptoms. Specifically, the treatments reduced mite counts by nearly 100% and improved itching and skin condition within one to two months. Both medications were found to be effective and safe for treating this skin condition in dogs.
People also search for: dog itching treatment · sarcoptic mange in dogs · NexGard for mange · dog skin problems treatment
Abstract
The efficacy of NexGardand NexGard Spectraagainst sarcoptic mange in dogs was evaluated in a clinical field study. Skin scrapings from dogs presenting signs suggestive of sarcoptic mange were examined to confirm infestation. A total of 106 dogs were screened at eight sites in Portugal and Germany. In all, 80 dogs that had demonstrated ≥5 live Sarcoptes mites in five skin scrapings were enrolled, scored for specific clinical signs (pruritus; papules and crusts; alopecia), and allocated at random to receive either NexGardor NexGard Spectratwice, one month apart per label instructions. To determine efficacy, live Sarcoptes mites in five skin scrapings per dog were counted, and clinical signs were scored one month and two months after first treatment and compared to pre-treatment (baseline) values. Based on compliance, 65 dogs were determined to be evaluable cases at the end of the study. The efficacy, in terms of reduction of geometric mean live Sarcoptes mite counts, was 98.9% and 99.7% for NexGard-treated (n = 38) and 99.6% and 100% for NexGard Spectra-treated dogs (n = 27) at one month and two months after treatment initiation (p < 0.001, both treatments). Both treatments resulted in a significant improvement in pruritus, papules and crusts, and alopecia one month and two months after treatment initiation (p = 0.0001, both treatments). In conclusion, this field study confirms that both NexGardand NexGard Spectraadministered twice one month apart provide an effective and safe treatment against sarcoptic mange in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30516132/